The comparison of the eGFR slope before and after the start of dapagliflozin treatment in the six patients for whom the slope could be calculated found that it improved in all patients except the one who was not taking an RAS inhibitor, and in all five patients for whom %ΔhtTKV/y could be calculated, %ΔhtTKV/y showed an increasing trend.
← all excerpts
Dapagliflozin treatment in patients with chronic kidney disease associated with autosomal dominant polycystic kidney disease.
1
—
—